Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors
Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.
Aim(s): We describe the clinical utility of the NETest to diagnose bronchopulmonary neuroendocrine tumors and define their clinical status.
Materials and methods: The discovery set included BPNETs (n=154) and controls (n=90), randomly assigned [1:1] to a test and validation set. Specificity was evaluated in adenocarcinoma (n=54) and squamous cell carcinoma: (n=37), other NENs (n=13), and COPD: (n=18). Clinical efficacy: disease presence versus absence was assessed in a surgical cohort (n=45) and progressive versus stable disease (n=154). Gene expression (NETest-PCR) and CgA (ELISA-Euro Diagnostica) levels were evaluated by non-parametric, ROC and Fisher’s test.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Modlin I
To read the full abstract, please log into your ENETS Member account.